BMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $134.00 (from $133.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Abbvie (ABBV) PT Raised to $132 at Mizuho SecuritiesNovember 1, 2021 4:54 AM Abbvie (ABBV) PT Raised to $118 at BarclaysNovember 1, 2021 4:39 AM Abbvie (ABBV ) PT Raised to $124 at Morgan StanleyNovember 1, 2021 2:44 AM AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat PresbyopiaOctober 29, 2021 5:33 PM